ERBB2 and neoplasm: Current predictive indicators mainly include clinicopathological factors such as tumor staging, histological type, tumor location and lymph node metastasis, as well as molecular biomarkers such as human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1) and microsatellite instability (MSI) (9–11).